All lobbying filings

Ferox Strategies

Ferox Strategies filed a Q3 report for Viatris Inc. on October 19, 2026, reporting $70,000 in lobbying income.

Lobbying for Viatris Inc. · Pharmaceutical company

As filed: FEROX STRATEGIES for VIATRIS INC.

All filings by Ferox Strategies · Everything Viatris Inc. has reported

Filing · LD-2 quarterly report Q3 report

Reporting period

3rd Quarter 2026

July 1 - Sep 30 · Posted Oct 19, 2026

Income

$70,000

What the client paid this registrant for the period.

Client based in

Pennsylvania

Official filing document

Government bodies contacted 6

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 2

Pharmacy

Policy and oversight related to the generic pharmaceutical industry. Issues related to drug pricing. Issues related to FDA generic drug approval process. General issues related to Agriculture Appropriations and National Defense Authorization Act (S. 1071).

Trade (domestic/foreign)

Trade issues related to generic medicines.

Bills named in this filing 1

S. 1071
National Defense Authorization Act for Fiscal Year 2026

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.